Safety and Performance Study of the NeoChord Device (TACT)

September 23, 2014 updated by: NeoChord

Safety and Performance Study of the NeoChord Suturing Device in Subjects With Degenerative Mitral Valve Disease; Diagnosed With Severe Mitral Regurgitation

The purpose of this study is to demonstrate the safety and performance of the NeoChord DS1000 Artificial Chordae Delivery System in implanting ePTFE sutures(s) as artificial neochordae in patients with mitral regurgitation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Aarhus, Denmark, 8200
        • Aarhus University Hospital, Skejby
  • Germany
      • Bad Nauheim, Germany
        • Kerckhoff-Klinik
      • Bad Neustadt, Germany
        • Herz und Gefäß-Klinik
      • Leipzig, Germany
        • Herzzentrum Leipzig
      • Munich, Germany
        • Klinik für Herz-und Gefäßchirurgie
  • Italy
      • Milan, Italy
        • San Raffaele
      • Torino, Italy
        • Ospedale San Giovanni Battista "Molinette"
  • Lithuania
      • Vilnius, Lithuania
        • Vilniaus Universiteto ligonines Santariskiu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 79 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age >= 18 and < 80 years
  • Candidate for surgical mitral valve repair or replacement
  • Isolated posterior leaflet prolapse
  • Moderate to severe or severe mitral valve regurgitation that is degenerative in nature

Exclusion Criteria:

  • Anterior or bi-leaflet prolapse
  • Functional or ischemic MR
  • NYHA Class IV
  • Complex mechanism of MR (leaflet perforation, etc)
  • Significant tethering of leaflets toward LV apex
  • Severely calcified mitral valve annulus
  • Inflammatory valve disease
  • Severe LV dilation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Implanting ePTFE sutures
Implanting ePTFE sutures as artificial neochordae using the NeoChord DS1000 Artificial Chordae Delivery System
Device: NeoChord DS1000 Artificial Chordae Delivery System

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Procedural Success
Time Frame: 30 days
The placement of at least one neochord using the DS1000 System AND a reduction in mitral regurgitation <= 2+ at the time of the procedure AND maintained MR reduction of <= 2+ at 30 days
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Procedural Safety
Time Frame: 30 days
the rate of Major Adverse Events (MAE) defined as a combined endpoint of: death, MI, reoperation for failed surgical repair, non-elective cardiovascular surgery to treat an adverse event, procedural ventilation > 48 hours, procedure-related transfusion of > 2 units blood product, stroke, renal failure, deep wound infection, new onset of permanent AF, and septicemia, through 30 days.
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

NeoChord

Investigators

  • Principal Investigator: Anno Diegeler, MD, Herz und Gefäß-Klinik

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2009

Primary Completion (Actual)

October 1, 2012

Study Completion (Actual)

August 1, 2014

Study Registration Dates

First Submitted

January 25, 2013

First Submitted That Met QC Criteria

January 25, 2013

First Posted (Estimate)

January 29, 2013

Study Record Updates

Last Update Posted (Estimate)

September 25, 2014

Last Update Submitted That Met QC Criteria

September 23, 2014

Last Verified

September 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PR-610404-100
  • 09/1819 (Other Identifier: FEKI)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mitral Valve Regurgitation

Clinical Trials on NeoChord DS1000 Artificial Chordae Delivery System

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe